|1.||Hedblad, Bo: 8 articles (06/2011 - 12/2002)|
|2.||Engström, Gunnar: 8 articles (06/2011 - 12/2002)|
|3.||Lindgärde, Folke: 8 articles (02/2009 - 12/2002)|
|4.||Janzon, Lars: 7 articles (03/2006 - 12/2002)|
|5.||Jin, Rui: 4 articles (07/2015 - 11/2011)|
|6.||Zhou, Guo-Ping: 4 articles (07/2015 - 11/2011)|
|7.||Zhuang, Li-Li: 4 articles (07/2015 - 11/2011)|
|8.||Hommel, E: 4 articles (07/2010 - 01/2002)|
|9.||Feldt-Rasmussen, B: 4 articles (07/2010 - 01/2002)|
|10.||Påhlsson, Peter: 4 articles (10/2009 - 03/2002)|
|1.||Crohn Disease (Crohn's Disease)
01/01/2000 - "Improvement in mean paediatric Crohn's disease activity index (PCDAI) was significantly more in group S (p = 0.002) but changes in orosomucoid level, platelet count, and weight were not different between the groups. "
12/01/1994 - "Serum levels of CRP and orosomucoid were measured simultaneously over a four year period in 13 patients receiving TPN for Crohn's disease, nine patients with noninflammatory causes of intestinal failure, and 16 patients with Crohn's disease treated without TPN. "
01/01/1991 - "Patients with Crohn's disease and the 51 kDa form (n = 39) had significantly higher values of activity index (CDAI) and orosomucoid than patients with Crohn's disease and the 38 kDa form (n = 26) (P less than 0.01). "
01/01/1989 - "Platelet number and size in relation to serum orosomucoid concentration in Crohn's disease."
09/01/1982 - "As the main evaluation criteria the Crohn's Disease Activity Index and plasma levels of orosomucoid were chosen. "
09/01/2000 - "The purpose of this study was to evaluate alpha 1-acid glycoprotein (AGP) concentrations in tumor-bearing and healthy cats. "
10/15/1988 - "In the present study, Cc was purified by a modified protocol which involved the use of pleural fluid obtained from individuals with cancer, and an alpha 1-acid glycoprotein antibody column to remove contaminating alpha 1-acid glycoprotein. "
03/01/1971 - "[Clinical studies on seromucoid concentration in malignant tumor]."
09/01/1967 - "[Immunoelectrophoretic study of seromucoid--its patterns in normal subjects and cancer patients]."
09/01/2011 - "Sixty-seven patients with advanced solid tumors were stratified by baseline plasma alpha 1-acid glycoprotein (AAG) levels and randomized to one of three vismodegib 150 mg regimens: QD (n = 23), TIW (n = 22), or QW (n = 22) for up to 42 days after an 11-day loading phase (150 mg QD). "
01/01/1988 - "Patients with active localized or advanced carcinoma had higher levels of orosomucoid than patients in remission (mean = 0.88 g/l). "
09/01/1992 - "Genetic study of orosomucoid by isoelectric focusing and immunoprinting in patients with carcinoma."
12/01/1977 - "Studies on seromucoid of patients with carcinoma of the uterine cervix."
01/01/1988 - "Orosomucoid increased with the progression of ovarian carcinoma. "
01/01/1972 - "[Immunologic demonstration of an acid alpha 1 glycoprotein in in-vivo neutralized gastric juice of patients with stomach carcinoma and metaplastic mucosal changes]."
08/01/1988 - "The actual correlation coefficients indicated a closer association with the other laboratory tests, CRP (0.62), orosomucoid (0.69), and ESR (0.61), than with clinical measurements: pain score (0.38), articular index (0.41), grip strength (-0.3), morning stiffness (0.19), and Mallya score (0.5). "
01/01/1979 - "The fasting patients showed reduced pain, stiffness, consumption of analgetics, several clinical variables, and serum concentration of orosomucoid. "
01/01/2003 - "Nimesil relieved pain and inflammation (ESR and seromucoid level lowered significantly). "
03/01/1991 - "The treatment group showed significant improvement in pain, stiffness, sleep disturbance (p less than 0.05), finger/floor distance, erythrocyte sedimentation rate, C-reactive protein, orosomucoid and IgA levels (p less than 0.01). "
11/01/1986 - "Burn injury, cancer, chronic pain syndrome, myocardial infarction, inflammatory diseases and trauma are all associated with elevations in the concentration of alpha 1-acid glycoprotein. "
01/01/2012 - "Orosomucoid (ORM), an acute phase reactant protein, was shown to be produced in response to metabolic and inflammatory signals in the adipose tissue of obese mice, which protects them from severe inflammation and subsequent metabolic dysfunction. "
07/16/2010 - "Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation."
01/01/2010 - "We therefore hypothesize that increased levels of UOER may be caused by local renal production of orosomucoid due to chronic low-grade inflammation."
01/01/2010 - "Serum values of orosomucoid were higher in patients with increased UOER than in healthy controls (P<.001), but were still within reference limits, suggesting chronic low-grade inflammation. "
01/01/2009 - "Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes."
|2.||N-Acetylneuraminic Acid (Sialic Acid)
|5.||Immunoglobulin A (IgA)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||beta 2-Microglobulin (beta 2 Microglobulin)
|9.||Apolipoproteins B (ApoB)
|1.||Drug Therapy (Chemotherapy)
|3.||Total Parenteral Nutrition
|5.||Renal Dialysis (Hemodialysis)